Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFENCE trial of denosumab in high-risk smoldering multiple myeloma and early myeloma
2018-000924-32Phase 2Completed
- Sponsor
- AGMT
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple myeloma (MM) and smoldering multiple myeloma (SMM) comparing Denosumab with Placebo (2 arms). Started Sep 2018; status: completed.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2018-000924-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000924-32.